PuSH - Publikationsserver des Helmholtz Zentrums München

Di Pilato, M.* ; Gao, Y.* ; Sun, Y.* ; Fu, A.* ; Grass, C. ; Seeholzer, T. ; Feederle, R. ; Mazo, I.* ; Kazer, S.W.* ; Litchfield, K.* ; von Andrian, U.H.* ; Mempel, T.R.* ; Jenkins, R.W.* ; Krappmann, D. ; Keller, P.*

Translational studies using the MALT1 inhibitor (S)-mepazine to induce Treg fragility and potentiate immune checkpoint therapy in cancer.

J. Immunother. Precis. Oncol. 6, 61-73 (2023)
Verlagsversion DOI PMC
Creative Commons Lizenzvertrag
INTRODUCTION: Regulatory T cells (Tregs) play a critical role in the maintenance of immune homeostasis but also protect tumors from immune-mediated growth control or rejection and pose a significant barrier to effective immunotherapy. Inhibition of MALT1 paracaspase activity can selectively reprogram immune-suppressive Tregs in the tumor microenvironment to adopt a proinflammatory fragile state, which offers an opportunity to impede tumor growth and enhance the efficacy of immune checkpoint therapy (ICT). METHODS: We performed preclinical studies with the orally available allosteric MALT1 inhibitor (S)-mepazine as a single-agent and in combination with anti-programmed cell death protein 1 (PD-1) ICT to investigate its pharmacokinetic properties and antitumor effects in several murine tumor models as well as patient-derived organotypic tumor spheroids (PDOTS). RESULTS: (S)-mepazine demonstrated significant antitumor effects and was synergistic with anti-PD-1 therapy in vivo and ex vivo but did not affect circulating Treg frequencies in healthy rats at effective doses. Pharmacokinetic profiling revealed favorable drug accumulation in tumors to concentrations that effectively blocked MALT1 activity, potentially explaining preferential effects on tumor-infiltrating over systemic Tregs. CONCLUSIONS: The MALT1 inhibitor (S)-mepazine showed single-agent anticancer activity and presents a promising opportunity for combination with PD-1 pathway-targeted ICT. Activity in syngeneic tumor models and human PDOTS was likely mediated by induction of tumor-associated Treg fragility. This translational study supports ongoing clinical investigations (ClinicalTrials.gov Identifier: NCT04859777) of MPT-0118, (S)-mepazine succinate, in patients with advanced or metastatic treatment-refractory solid tumors.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Malt1 ; Cancer Immunotherapy ; Fragile Tregs ; Interferon-γ ; Regulatory T Cells
ISSN (print) / ISBN 2666-2345
e-ISSN 2590-017X
Zeitschrift Journal of Immunotherapy and Precision Oncology
Quellenangaben Band: 6, Heft: 2, Seiten: 61-73 Artikelnummer: , Supplement: ,
Verlag Innovative Healthcare Institute
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Signaling and Translation (SAT)
CF Monoclonal Antibodies (CF-MAB)